Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Mohsen Amini
Total Records ( 3 ) for Mohsen Amini
  Seyed Nasser Ostad , Mohsen Amini , Zahra Haghipour , Leila Karimi and Latifeh Navidpour
  Recent studies have suggested cyclooxygenase-2 (COX-2) expression as a mechanism involved in carcinogenesis. It has also been suggested that changes in COX-2 expression level can be considered as a possible therapeutic target in tumors. Therefore, it was decided to synthesize a new series of 4, 5-diaryl thiadiazoles (compounds 1-5) as COX-2 inhibitors and evaluate their inhibitory activity on COX-2 expression. The COX-2 expression was induced by lipopolysaccharide (LPS) in bovine aortic endothelial (BAE-1) cells and the protein expression was evaluated by immunocytochemistry (ICC). The inhibitory activity of these compounds has been compared with celecoxib and rofecoxib as selective COX-2 inhibitors and indomethacin as a non-selective COX inhibitor. The cytotoxicity of these compounds was measured in different concentrations (10-3 -103 μg mL-1 ) by trypan blue dye exclusion method. The results showed that the cell viability following exposure to 10-2 μg mL-1 of each one of compounds 1-4 was about 90%. Among all tested compounds, compound 4 at 10-2 μg mL-1 showed significant inhibition on COX-2 expression determined by ICC. This effect of compound 4 was comparable to rofecoxib and celecoxib. It is concluded that, the new synthesized compounds and in particular, the compound 4 can be considered for further evaluation as new COX-2 inhibitors.
  Mohsen Amini , Morteza Pirali-Hamedani , Hossein Ali Ebrahimi , Majid Darabi and Abbas Shafiee
  A HPLC method for determination of rofecoxib in human serum was presented. The method is based on pre-column derivatization of analyte to a phenanthrene derivative of drug. Rofecoxib and internal standard were extracted from serum using liquid-liquid extraction. Upon exposure to UV light, drug was found to undergo a phtocyclization reaction giving a species with high absorbance. Validation of the method has been studied in the concentration range of 2-100 ng mL-1.
  Hossein Khedmat , Mohsen Amini , Amir Masoud Jafari , Farhad Nasiri Afshar and Morteza Izadi
  In the present study we investigated the existence of duodenal ulcer activity monthly changes and clarify the roles played by gender, age and Helicobacter pylori We performed a hospital based cross sectional study of 939 patients with an incident duodenal ulcer out of 4339 dyspeptic patients from April 2004 to March 2006 in Baqihyatollah University of Medical Sciences, Tehran, Iran. On endoscopy two biopsy specimens were taken from antral gastric greater curvature within approximately 3 cm from the pylorus for rapid urease test. The number of duodenal ulcers and percentage of HP infection with regard to the time of evaluation were analyzed. There was a significance increase in the occurrence of duodenal ulcer in cold period of the year (autumn and winter), (p< 0.0005, χ2 = 18.1), After applying adjustment for age, gender and the year of evaluation, there was Also an increment in the percentage of HP infection in cold period of year in comparison to hot one (spring and summer), (p = 0.009, Odds ratio = 1.6, 95%CI 1.1-2.3). The present findings indicate that the observed duodenal ulcer occurrence increment in some cold months of the year was a manifestation of the cold month`s increments in percentage of HP infection diagnosis in dyspeptic patients who come to our center. For clarification of the biological basis of this phenomenon, further studies, including the interactions of climate, HP and neuroendocrine transmitters and usage of a reliable diagnostic method capable of distinguishing recent from old HP infection may be required.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility